J&J to Spend More on R&D With Tax Reform Money

J&J Terminates RA and Leukemia Drug From Pipeline

J&J Terminates RA and Leukemia Drug From Pipeline

But for now, the world’s biggest healthcare company isn’t providing many details on how it may use the extra money from lower tax rates.


Johnson & Johnson is promising to spend more on research in the health-care sector after changes to the U.S. tax system.

But for now, the world’s biggest health-care company isn’t providing many details on how it may use the extra money from lower tax rates.

“We’re going to look at all of our opportunities but it’s going to be a significant increase,” Chief Financial Officer Dominic Caruso said Tuesday in an interview on Bloomberg TV.

MORE ON THIS TOPIC